Skip to main content
letter
. 2020 Sep 3;8(2):109–110. doi: 10.5152/eurjrheum.2020.20080

Figure 1.

Figure 1

18-month drug survival of originator bDMARDs (boDMARDs) and biosimilar bDMARDs (bsDMARDs) treatment.